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Abstract 
Among patients with acute coronary syndromes (ACS), those with diabetes mellitus (DM) are 
at particularly high risk of recurrent cardiovascular events and premature death. We aimed to 
provide a descriptive overview of unadjusted analyses of patient characteristics, ACS 
management, and outcomes up to 1 year after hospital admission for an ACS/index-ACS event, 
in patients with DM in contemporary registries in Europe.  
A total of 10 registries provided data in a systematic manner on ACS patients with DM (total n= 
28,899), and without DM (total n= 97,505). In the DM population, the proportion of patients 
with ST-Segment Elevation Myocardial Infarction (STEMI) ranged from 22.1% to 100.0% (other 
patients had non-ST-Segment Elevation Myocardial Infarction (NSTEMI-ACS) or unstable 
angina). All-cause mortality in the registries ranged from 1.4% to 9.4% in-hospital; 2.8% to 
7.9% at 30 days post-discharge; 5.1% to 10.7% at 180 days post-discharge; and 3.3% to 10.5% 
at 1 year post-discharge. Major bleeding events were reported in up to 3.8% of patients while 
in hospital (8 registries); up to 1.3% at 30 days (data from two registries only), and 2.0% at 1 
year (one registry only). Registries differed substantially in terms of study setting, site, patient 
selection, definition and schedule of endpoints, and use of various P2Y12 inhibitors. In most, 
but not all, registries, event rates in DM patients were higher than in patients without DM. 
Pooled risk ratios comparing cohorts with DM vs. no DM were in-hospital significantly higher in 
DM for all-cause death (1.66; 95% CI 1.42-1.94), for cardiovascular death (2.33; 1.78 - 3.03), 
and for major bleeding (1.35; 1.21-1.52).  
These registry data from real-life clinical practice confirm a high risk for recurrent events 
among DM patients with ACS, with great variation across the different registries. 
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Introduction 
In recent years, substantial progress has been achieved in the management of patients with 
acute coronary syndromes (ACS). The ACS spectrum comprises, based on electrocardiographic 
criteria and troponin biomarker criteria, ST-segment elevation myocardial infarction (STEMI), 
non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA).1 
Percutaneous coronary intervention (PCI), usually combined with dual antiplatelet therapy 
(DAPT), is now the default therapeutic strategy in these patients. The combination of a P2Y12 
receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) with acetylic salicylic acid (ASA, aspirin) 
has been proven to reduce the risk of recurrent cardiac events while having an acceptable 
safety profile, in particular with regard to bleeding events. 2, 3 
Both the non-ST-segment elevation acute coronary syndromes (NSTE-ACS, either NSTEMI or 
UA) and STEMI guidelines of the European Society of Cardiology highlight the particular 
concerns for patients with diabetes mellitus (DM) in the management of ACS. 2, 3 Irrespective 
of the type of DM, these patients are categorised as having a very high risk of recurrent 
cardiovascular events, translating into a doubled risk of premature death.4  Observational 
studies, including the Euro Heart Survey in 2004 and newer studies, indicate that these 
patients do not always receive the aggressive pharmacological treatment that is necessary to 
reduce their risk of recurrent events. 5-7 
A number of registries in Europe have collected current information on the characteristics and 
outcomes of patients with ACS. The “Platelet Inhibition Registry in ACS EvalUation Study” 
(PIRAEUS) group consists of experts in cardiology who are managing national or international 
ACS registries in Europe (authors of this article). In previous publications, the PIRAEUS working 
group published an overview of the scope and methods of the various contemporary ACS 
registries,8 and separate papers on the characteristics and outcomes up to 1 year in patients 
with STEMI9 and NSTE-ACS 10. Now, we have analysed the same registries to assess the 
characteristics, treatments, and outcomes (deaths, cardiac events, bleeding) in patients with 
DM type 1 or type 2. 
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Methods 
To select appropriate contemporary registries of ACS patients, the following criteria were 
applied: European multicentre or single-centre observational studies of real-life experience in 
the management of ACS from 2010 to 2015; large unselected patient cohorts; availability of 
data on PCI; availability of data on management during initial hospitalisation for ACS; 
availability of follow-up data on outcomes (death, cardiac events, bleedings); previous 
publication of data in peer-reviewed journals and/or reporting of unpublished data, with 
information on outcomes of drug treatment with P2Y12 receptor inhibitors, at least until 
discharge of the patient from the hospital; willingness of registry owners to take part in 
PIRAEUS and share data.  
For the present analysis, registries needed to present information about DM status according 
to clinical diagnosis (diabetic or nondiabetic, irrespective of type 2 or type 1). Information was 
collected, but was not mandatory, about mean HbA1c level, and diabetes-related treatment 
(e.g. insulin or other antidiabetic drugs) or complications (including neuropathy, retinopathy, 
and nephropathy).  
Registry owners shared data (a) on the ACS cohort categorised by DM status (present or 
absent) and (b) within the DM and non-DM groups, on subgroups of patients treated with the 
P2Y12 receptor inhibitors prasugrel, ticagrelor, or clopidogrel.  
Only aggregate data in tabular format were received, as the pooling of individual patient data 
was not covered by patients’ informed consent and/or was not possible due to data ownership 
issues. The data collection sheet specified time points at discharge from hospital, at 30 days 
post-discharge, at 180 days post-discharge, and at 1 year post-discharge. Endpoints of interest 
were all-cause death, cardiovascular death, stroke, recurrent myocardial infarction (MI), and 
repeat PCI (for efficacy), as well as fatal/life-threatening, major, and minor bleeding events (for 
safety). For bleeding events, the definition used by each registry was requested from the 
registry owners, but was not always available or sometimes had changed during the course of 
the registry data collection.  
Registry owners were asked to provide percentages for the various events, together with 
number of events and number of patients at the various time points. Data were not adjusted 
or weighted.  
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Statistical analysis. For the current paper, aggregate data on patients from 10 registries were 
included for statistical analysis. The aggregate patient data were used by a statistician to 
calculate event rates for the total cohort and by DAPT regimen specifically, with two-sided 95% 
confidence intervals (CI) using the Clopper-Pearson interval. Cohorts comprising fewer than 50 
patients with DM and 100 patients without DM were excluded from analyses because of the 
small number of events. Thus, data from DIOCLES on prasugrel, and data from Newcastle 2015 
and SPUM-ACS on ticagrelor were not included in analyses due to the small number of 
patients. Event rates were defined as cumulative incidence rates. Event rates and 95% CI for 
each cohort are shown using forest plots. Risk ratios with 95% CI comparing cohorts with DM 
vs. no DM using the DerSimonian and Laird method for a random-effects model are also shown 
in forest plots. Bubble plots confirmed the relationship between age and event rates whereby 
the size of the bubble represents the number of patients in the respective subgroups. These 
analyses were sent to the individual registry holders for confirmation of the data, entry of 
corrections, and, if indicated, provision of additional data. 
A description of the registries that provided data for this analysis can be found in the online 
supplement, part 1.  
 
Online supplement part 1 
ACS REGISTRIES THAT PROVIDED DATA ON ACS PATIENTS BY DIABETES STATUS FOR THE 
CURRENT EFFECTIVENESS AND SAFETY ANALYSES  
AAPCI/ADAPT (Austria). The Austrian Acute PCI registry (AAPCI) is a nationwide, prospective, 
multicentre, observational registry of interventional reperfusion therapy in acute MI. Since its 
implementation in 2005, it evaluates interventional therapy and determines predictors of 
successful treatment and in-hospital outcome in patients receiving coronary intervention in a 
real-world setting of AMI.11 Patients are eligible for documentation if they were admitted with 
AMI to one of the participating centres within 24 h (STEMI) or 72h (NSTE-ACS) of symptom 
onset.  
The registry collects data on demographics, cardiac history with previous coronary 
intervention and previous MI, mode of admission, key time points and intervals to describe the 
event and intervention, the intervention itself together with drug treatment details, and the 
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outcomes. Data from the registry allow a comparison of the outcomes of STEMI or NSTE-ACS 
treatment with each of the three available P2Y12 receptor inhibitors. 
The Austrian Dual Antiplatelet Therapy Registry ADAPT is a sub-registry established to 
specifically address effectiveness and safety of ticagrelor and prasugrel in real-world PCI in 
ACS.  
AMIS Plus (Switzerland). The Acute Myocardial Infarction in Switzerland (AMIS) registry was 
started in 1997 to prospectively collect real-life data on STEMI and NSTE-ACS patients.12 In 
2000 it was renamed AMIS Plus after the extension to patients with unstable angina (UA).  
Since 2005, a subset of hospitals also collects follow-up information on about half of the ACS 
patients 1 year after hospital discharge via telephone interviews and questionnaires. 
Participating hospitals include all types from regional to large tertiary centres. In 2010, out of 
106 hospitals in Switzerland treating ACS patients 76 temporarily or continuously contributed 
patients to AMIS Plus. 
The data from the AMIS Plus registry are used to characterise examination and treatment 
strategies of patients with acute MI and UA, to assess compliance with guidelines, and to guide 
the optimisation of interventions. 
The data of the registry allow for a direct comparison of the outcomes of the DAPT for all three 
P2Y12 receptor inhibitors. To date, the registry collected data from more than 51,000 patients.  
ATACS (Germany). The ATACS (Antithrombotic Therapy in patients with Acute Coronary 
Syndrome) registry is a sub-registry of the ALKK coronary angiography and PCI registry. For the 
ATACS registry in the 30 participating hospitals between October 2009 and February 2013 
specific information on timing and dosing of clopidogrel and prasugrel, risk factors for bleeding 
complications and timing and outcome of bleedings were added to the standard 
questionnaire. The registry focused on ACS patients and the results of the STEMI patients 
scheduled for primary PCI, receiving a loading dose of either clopidogrel or prasugrel.13 
Belgian STEMI registry. The Belgian STEMI registry is a prospective observational multicentre 
study initiated in 2007. All Belgian hospitals irrespective of size and care level are eligible for 
participation if they have an acute care facility; currently 72 hospitals contribute data. The 
registry focuses on the documentation of consecutive patients with (suspected) STEMI.  
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Pre-existing clinical conditions such as CAD or PAD are documented, apart from comorbidities 
such as diabetes or kidney disease.  Only for a subgroup of 2279 patients details on the 
outcomes of the different DAPT treatments are available. For these patients, more information 
about comorbidities such as diabetes or CAD is provided. About 60% of these patients were 
treated with ticagrelor, 28% with prasugrel and only 12% with clopidogrel. There are data for 
in-hospital death of the total cohort and for the patients who underwent DAPT therapy.  
CZECH-2 (Czech Republic). CZECH-2 was a prospective multicentre, observational, regional 
survey performed in 2012, in which all 28 hospitals without catheterisation availability and all 
4 cardiology centres with non-stop PCI service in the 4 Czech counties (out of 14 existing 
counties) participated (100% hospitals in participating regions). 14 The registry documented all 
consecutive STEMI, NSTE-ACS and UA. Patients were treated with prasugrel or clopidogrel, but 
not ticagrelor (not available in the Czech Republic at the time of registry initiation).  
DIOCLES (Spain). DIOCLES study is a prospective, multicentre, registry in Spain, which 
documented STEMI, NSTE-ACS, and UA patients limited to a documentation period in 2012 and 
a 6-month follow-up. 15 Except for pre-hospital ACS treatment, the registry summarises all 
details of enrolled patients, including complete clinical histories and comorbidities. The 
DIOCLES registry documents outcomes for DAPT treatment with clopidogrel or prasugrel, 
however, the size of the prasugrel group is a tenth of the clopidogrel group.  
MULTIPRAC (international). MULTIPRAC ( “MULTInational non-interventional study of patients 
with ST-segment Elevation Myocardial Infarction Treated with PRimary Angioplasty and 
Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel”) was a 
prospective open-label non-interventional international study, performed between June 2011 
and June 2013 in 25 large centres.16 Only large expert centres were selected for participation; 
they needed to perform at least 100 primary PCIs per year, were part of an admission network, 
and had a clearly defined pre-hospital treatment practice with thienopyridines in place. Only 
STEMI patients were eligible. As opposed to many other registries, they had to receive pre-
hospital prasugrel or clopidogrel loading immediately after diagnosis and prior to/during 
ambulance transport to a cathlab hospital for primary PCI (pre-hospital DAPT treatment, 
upstream DAPT treatment). The study is one of the few reporting 1-year outcome data. 17  
Newcastle dataset (UK). The Newcastle STEMI dataset is not a typical registry, but a 
retrospective analysis of prospectively collected data of the Freeman Hospital, Newcastle-
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upon-Tyne, in the Northeast of England. Freeman Hospital is a regional tertiary centre serving 
a population of approximately 2 million and performing over 850 primary PCI cases per year. 
STEMI cases from 2010 to 2013 are reported, however without comparisons of different DAPT 
regimens. 18 
SCAAR (Sweden). SCAAR (Swedish Coronary Angiography and Angioplasty Registry) is a 
prospective multicentre registry, which since 1990 documents all consecutive coronary 
angiographies and PCI procedures performed in Sweden.19 Data from SCAAR are reported 
annually.20 The registry covers all regions of Sweden and all 29 hospitals with a catheterization 
laboratory and enrolls STEMI, NSTE-ACS and UA patients (in addition to angiography 
performed for any other reason). Data on all three P2Y12 receptor inhibitors are available.  
SPUM-ACS (Switzerland). The SPUM-ACS (Special Program University Medicine-Acute 
Coronary Syndromes) research network collects data since 2009 on a prospective cohort of 
patients hospitalised for an ACS in 4 university medical centres in Switzerland (Bern, Geneva, 
Lausanne and Zurich). 21 It includes STEMI, NSTE-ACS, UA and elective stable angina patients.  
In Cohort 1 (recruited between 9/2009 and 10/2012), as per protocol and according to the ESC 
Guidelines, patients were treated with DAPT after PCI with clopidogrel (NSTE-ACS, STEMI <60 
kg or >75 years or history of TIA or stroke) or prasugrel/ticagrelor (other STEMIs).22 Treatment 
details in hospital were not given, but outcomes of treatment with all three P2Y12 receptor 
inhibitors were reported.     
 
End of Online supplement -   
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Results 
In total, 10 registries (AAPCI/ADAPT, AMIS Plus, ATACS, Belgian STEMI, CZECH-2, DIOCLES, 
MULTIPRAC, Newcastle, SCAAR, and SPUM-ACS) had information about patients with and 
without DM (Table 1); however, none differentiated between type 1 and type 2 DM , with the 
exception of CZECH-2. Belgian STEMI and CZECH-2 did not provide P2Y12-specific data. The 
other registries provided specific data on patients treated with clopidogrel and prasugrel 
(exceptions: Belgian STEMI, CZECH-2, Newcastle), and five registries provided specific data on 
ticagrelor (no such data were provided by Belgian STEMI, CZECH-2, ATACS, DIOCLES, or 
MULTIPRAC). 
 
In the DM population, the proportion of patients with STEMI ranged from 22.1% (DIOCLES) to 
64.6% (AAPCI/ADAPT) , while the other patients had NSTEMI or UA as the index diagnosis. 
MULTIPRAC and Belgian STEMI only reported STEMI data. 
Characterisation of patients with DM  
The number of patients with DM in the different registries varied widely, between 279 
(MULTIPRAC) and 19,794 (SCAAR). The mean age of DM patients in the registries varied 
between 64.0 years (MULTIPRAC) and 71 years (DIOCLES and CZECH-2).. There were more 
male than female patients in all registries.  
The prevalence of previously diagnosed coronary artery disease (CAD) varied substantially, 
from 24% (Belgian STEMI) to 100% (ATACS, with this rate due to the fact that CAD was an 
inclusion criterion) and prior MI rates ranged from 17.2% (MULTIPRAC) to 39.0% (Newcastle). 
Prior stroke ranged from 4.3% (SPUM-ACS) to 13.3% (SCAAR).  
Information on diabetes laboratory values, and on related complications, was limited. The 
incidence of diabetic nephropathy was reported in the SCAAR study (27.2%) and DIOCLES 
registry (severe chronic kidney disease in 9.2%) only. The incidence of retinopathy or 
neuropathy was not reported in any registry. HbA1c values were given only in the SPUM-ACS 
study (mean value 7.6%). The proportion of patients who received insulin treatment was 
between 27.6% (MULTIPRAC) and 48.8% (SCAAR). 
The rates of chronic aspirin treatment as long-term treatment for preexisting CAD (unrelated 
to the index ACS event) varied, between 29.4% (MULTIPRAC) and 56.8% (AMIS Plus). Pre-
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event, chronic treatment with P2Y12 inhibitors was reported in all registries with the exception 
of AAPCI/ADAPT and Belgian STEMI, with clopidogrel reported between 3.9% (MULTIPRAC) 
and 21.7% (ATACS), and prasugrel between 0% (CZECH-2) and 3.6% (ATACS).  
Treatment for the ACS index event 
In the context of the index ACS event, pre-treatment use of P2Y12 inhibitors (during transport; 
after onset of the event but before admission to the hospital) was reported in AAPCI/ADAPT 
(29.4% of patients received clopidogrel, 12.1% prasugrel, and 12.0% ticagrelor), MULTIPRAC 
(60.9% clopidogrel, 39.1% prasugrel), SCAAR (48.8% clopidogrel, 1.8% prasugrel, 16.5% 
ticagrelor), and SPUM-ACS (14.8% clopidogrel, 3.2% prasugrel, 0.8% ticagrelor).  
In-hospital, almost all patients received loading doses of P2Y12 inhibitors for the treatment of 
the index ACS event. Switching between drugs in this class varied substantially (e.g. 45.3% in 
MULTIPRAC; 7.7% in AMIS Plus, 2.3% in SPUM-ACS for switching from clopidogrel to 
prasugrel).  
The time of first medical contact to PCI is relevant for STEMI patients. This time value varied 
substantially in the five registries that reported this information, ranging from about 1.5 hours 
(MULTIPRAC) to almost 6 hours (SCAAR).  
The great majority of patients received coronary angiography (70.4% in CZECH-2, 81.3% in 
DIOCLES, 85.5% in AMIS Plus, and 100% each in MULTIPRAC, SCAAR, SPUM-ACS, AAPCI/ADAPT, 
and ATACS).  
Reported PCI varied between 55.5% (DIOCLES) and 94.7% (SPUM-ACS), and revascularisation 
was reported in 97.5% of patients in MULTIPRAC. Radial access for PCI, where reported, varied 
between 24.8% (ATACS) and 71% (DIOCLES).  
 
Outcomes  
For various ischaemic and bleeding outcomes, event rates are presented descriptively for all 
diabetic patients (Table 2) and by P2Y12 inhibitor (Table 3). Further, they are plotted against 
mean age of the patients in each respective group (bubble plots in the online supplement).   
 
a. Ischaemic outcomes  
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All-cause death rates in diabetic patients ranged from 1.43% (MULTIPRAC) to 9.42% (Belgian 
STEMI) in-hospital, based on data from 28,899 patients; from 2.76% (SPUM) to 7.93% (CZECH-
2) at 30 days post-discharge; from 5.11% (Newcastle) to 10.72% (DIOCLES) at 180 days post-
discharge, and from 3.27% (MULTIPRAC) to 10.45% (SCAAR) at 1 year post-discharge.  
Cardiovascular death rates were only reported in three registries. In-hospital cardiovascular 
death rates were 1.43% (MULTIPRAC), 2.26% (SPUM-ACS), and 2.98% (AMIS-Plus). At 30 days 
post-discharge, the rate was 2.51% (data from SPUM-ACS only), and at 1 year, the rates were 
1.82% (MULTIPRAC) and 5.60% (SPUM-ACS).  
Stroke events were reported in eight registries (all except Newcastle and Belgian STEMI). 
SCAAR provided stroke information data after discharge, but no in-hospital stroke data. Event 
rates ranged from 0% (CZECH-2) to 1.00% (SPUM-ACS) in-hospital. Post-discharge stroke 
events ranged from 0.34% (CZECH-2) to 1.76% (SPUM-ACS) at 30 days; from 1.31% (DIOCLES) 
to 1.67% (SCAAR) at 180 days; and from 0.76% (AMIS-Plus) to 3.56% (SPUM-ACS) at 1 year.  
Recurrent in-hospital MI reported by seven registries ranged between 0% (MULTIPRAC) and 
1.78% (DIOCLES). After discharge, the recurrent MI rate was between 1.38% (CZECH-2) and 
7.94% (SCAAR) at 30 days; 3.01% (DIOCLES) and 13.45% (SCAAR) at 180 days; and between 
5.33% (AMIS Plus) and 16.32% (SCAAR) at 1 year.  
Repeat PCI rates varied widely, between 0.33% (CZECH-2) and 12.89% (AAPCI/ADAPT) in-
hospital; 1.03% (CZECH-2) and 2.01% at 30 days (SPUM-ACS) (no data from other registries 
were available); and 7.89% at 1 year (SPUM-ACS, no data from other registries available). No 
data for repeated PCI were available at 180 days from any registry. 
Overall, patients with DM, compared with those without DM, had higher event rates (Figures 1 
and 2). As a notable exception, in the CZECH-2 study, DM patients had a lower mortality, and 
in all studies (exception AMIS-Plus in-hospital but not at 1 year), DM patients had lower MI 
recurrence rates. Pooled risk ratios comparing cohorts with DM vs. no DM were in-hospital 
significantly higher in DM for all-cause death (1.66; 95% CI 1.42-1.94), for cardiovascular death 
(2.33; 1.78 - 3.03), but not for the other efficacy outocomes (Figure 2).  
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Efficacy outcomes by DAPT  
Ischaemic endpoints for each of the three P2Y12 inhibitors are displayed in Table 3 and in 
Figure 3. Data from 14,932 patients on clopidogrel, 2,252 on prasugrel, and 5,064 on ticagrelor 
were available for the analysis of in-hospital, all-cause death for patients with DM.  
Univariate analyses showed that patients on prasugrel, despite being substantially younger, 
had all-cause, in-hospital mortality rates that were similar to those of patients on clopidogrel 
(but tended to be lower compared with those on ticagrelor). The named figures in this 
manuscript and an additional 28 bubble plot graphs in the online supplement display the 
various ischaemic outcomes at the different time points.  
 
b. Bleeding  
The studies used various bleeding definitions: AAPCI, CZECH-2, and FAST-MI used the defini-
tion of Thrombolysis in Myocardial Ischemia (TIMI),23 and AMIS-Plus used the definition of the 
Bleeding Academic Research Consortium (BARC).24 ATACS used the definition of GUSTO,25 and 
the other registries used unspecified or proprietary definitions as displayed in Table 1. Overall, 
the data on the various bleeding types and documentation time points were less complete 
than the data on ischaemic outcomes. AMIS-Plus, DIOCLES, SCAAR and SPUM-ACS were the 
only registries to report various degrees of bleeding (Tables 2 and 3, bottom), and SCAAR and 
SPUM-ACS were the only registries that reported bleeding event rates beyond the 
hospitalisation phase.  
In-hospital bleeding event rates and risk ratios, by endpoint type and registry, are summarised 
in Figures 4 and 5, respectively. Data on fatal/life-threatening bleeding during hospitalisation 
were available from four studies (AMIS-Plus, DIOCLES, SCAAR, and SPUM-ACS). Rates during 
this in-hospital time frame fell within a considerable range, between 0.02% (SCAAR) and 1.75% 
(SPUM-ACS). At 30 days post-discharge, the rate in SPUM-ACS was 1.76%, and at one year, the 
rate in SPUM-ACS was 1.78% (data for 30 days and 1 year post-discharge were available only 
from SPUM-ACS; no data were available for 180 days post-discharge from any of the 
registries). 
For major bleeding events, the database was richer. Eight studies reported major bleeding 
events in-hospital, with rates ranging from 0.66% (CZECH-2) to 3.82% (DIOCLES) of patients. 
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Rates at 30 days post-discharge were available from only two studies (1.03% in CZECH-2 and 
1.26% in SPUM-ACS). One-year data were available only for SPUM-ACS; the rate was 2.04%. 
Minor bleeding events were reported in three studies for the in-hospital period. The minor 
bleeding rates during this period were 1.62% (AMIS-Plus), 2.01% (SPUM-ACS), and 2.87% 
(MULTIPRAC). At 30 days, the rate was 2.01% (SPUM-ACS) and at 1 year, it was 4.33% (SPUM-
ACS, no data from other studies were available).  
Despite the caveat of wide confidence intervals, overall, patients with DM appeared to have 
higher rates of fatal/life-threatening or major bleedings than patients without DM (Figure 5). 
However, there were exceptions; e.g. for fatal/life threatening bleeding in AMIS-Plus and 
SCAAR, or for major bleeding in CZECH-2. Pooled risk ratios comparing cohorts with DM vs. no 
DM were in-hospital significantly higher in DM for major bleeding (1.35; 1.21-1.52), but not for 
fatal bleeding or minor bleeding.   
 
Bleeding outcomes by DAPT  
Bleeding event patterns were inconsistent across registries for the three P2Y12 inhibitors in 
the incidence of bleeding rates for fatal/life-threatening, major, or minor bleeding in hospital 
in the univariate analyses. Fatal/life-threatening bleeding rates were generally lower on 
prasugrel compared with clopidogrel and ticagrelor (Figure 6).  
The bubble plot graphs in the online supplement display the various bleeding outcomes at 
different time points; data were adjusted for patient age.  
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DISCUSSION 
The present overview complements the picture gained from our previous analyses on the 
characteristics and outcomes of ACS patients with STEMI9 and NSTE-ACS10 (treated) in various 
European countries. It takes a different angle as it does not differentiate between the ACS 
groups, as otherwise group sizes would have become too small for meaningful statistical 
analyses.   
The majority of registries reported data on clopidogrel and prasugrel. Of the three drugs, 
ticagrelor was introduced into clinical practice most recently. Therefore, it was documented in 
a relatively low number of patients overall, and not at all in three registries (ATACS, 
MULTIPRAC, DIOCLES). As in our previous analyses, 9,10  we noted relevant differences in 
patient characteristics between the three P2Y12 inhibitors. Across registries, prasugrel was 
predominantly used in younger patients as compared with ticagrelor, and patients on 
clopidogrel constituted the oldest population. Thus, in clinical practice the age restrictions for 
prasugrel and other labelling recommendations for the individual P2Y12 inhibitors were 
observed.  
Efficacy outcomes 
Patient characteristics at entry and availability of endpoint data varied substantially, which 
makes comparisons with the phase III trials of the three P2Y12 inhibitors difficult. However, it 
appears that in the registries the event rates are overall higher compared with the randomised 
clinical trials (RCTs), which is likely due to the inclusion of a less selected and sicker population.   
Across registries, differences in reported outcomes were profound. The range of all-cause 
mortality (including patients on all three P2Y12 inhibitors) during the in-hospital period varied 
widely, between 1.43% in MULTIPRAC and 9.42% in the Belgian STEMI registry. This may 
reflect differences in patient selection, but could also be the consequence of structural factors 
(e.g. time from admission to PCI) or patient management, including P2Y12 inhibitor selection. 
Stroke rates among patients while still in hospital fell within a narrower range, between 0% in 
CZECH-2 and 1.00% in SPUM-ACS. However, for repeat PCI, the differences were enormous, 
ranging from 0.33% in CZECH-2 to 12.89% in AAPCI. The latter endpoint, repeat PCI, depends 
on the setting and the clinical decision rules of the respective centre and is therefore 
investigator-driven.  
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Across nearly all registries, patients with DM had consistently higher event rates compared 
with those without DM. As notable exceptions, DM patients included in the AMIS-Plus registry 
were the only ones with a higher rate of in-hospital recurrent acute myocardial infarctions as 
compared with the patients enrolled in all other registries (but not at 1 year), and in CZECH-2, 
lower mortality was seen in patients with DM.  
We did not perform effectiveness comparisons between the individual P2Y12 inhibitors. This is 
based on the considerable differences in patient numbers (low in ticagrelor), but also on the 
profound differences in patient characteristics, especially age. Age has been established as a 
central factor in major cardiovascular risk equations, including the TIMI and GRACE scores, and 
is closely correlated with ischaemic and bleeding events in patients with ACS. 26, 27 Given the 
fact that younger patients have fewer comorbidities, and are generally less ill or at lower 
cardiovascular risk, the outcomes in the three P2Y12 inhibitor subgroups need to be 
interpreted with great caution if not adjusted for age. Thus, the PIRAEUS data can be used to 
obtain a general overview of the current treatment approaches and outcomes but these data 
are not suitable for comparisons between the DAPT regimens.  
Nevertheless, the outcomes can be appreciated from the perspective of comparison with the 
RCTs of the three P2Y12 inhibitors: In the comparison of clopidogrel vs. placebo in NSTE-ACS 
(CURE study), the event rate was higher in subjects with DM, but the primary efficacy outcome 
did not differ significantly between patients with DM and those without. 28 The same was 
found in the CURRENT OASIS 7 study comparing 7-day high-dose vs. low-dose clopidogrel DAPT 
in ACS patients scheduled for early PCI.29 
The study on prasugrel versus clopidogrel (TRITON-TIMI 38) was the first to show in an 
adequately sized trial that intensified antiplatelet treatment improves outcomes in diabetic 
patients with ACS.30 In the 3,146 patients with diabetes history, the primary composite 
endpoint (CV death, MI, stroke) was reduced significantly with prasugrel among subjects 
without DM (9.2% vs. 10.6%; hazard ratio (HR): 0.86; p=0.02) and with DM (12.2% vs. 17.0%; 
HR: 0.70, p<0.001, P for interaction 0.09). A benefit for prasugrel was observed among DM 
subjects on insulin as well as those not on insulin. MI was reduced in prasugrel-treated 
patients by 18% among subjects without DM (7.2% vs. 8.7%; HR: 0.82; P=0.006) and by 40% 
among subjects with DM (8.2% vs. 13.2%; HR: 0.60; P<0.001, P for interaction 0.02). 30  
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Results were less clear for ticagrelor: In the phase III RCT on ticagrelor vs. clopidogrel in ACS 
(PLATO), in the 4,662 patients with DM, ticagrelor reduced the primary composite endpoint 
(HR: 0.88, 95% CI: 0.76-1.03) and also, separately, all-cause mortality (HR: 0.82, 95% CI: 0.66-
1.01) and stent thrombosis (HR: 0.65, 95% CI: 0.36-1.17). 31 This benefit was consistent 
between patients with and without insulin therapy, and was also consistent with the overall 
trial results, but did not reach nominal statistical significance.31 
Bleeding outcomes 
With respect to bleeding events, it should be noted that these were not standardised across 
registries, and in some registries the definitions were not given. The lack of uniformity in 
bleeding definitions and the timing of reporting among recent ACS and PCI clinical trials and 
registries has been highlighted previously,24 and uncritical comparisons of the absolute 
bleeding rates may be misleading in the interpretation of the safety of the various P2Y12 
antagonists. Across the registries, the bleeding rates for the various endpoints in the DM 
groups were similar to those in the non-DM groups (however, the latter had narrower 95% CI 
due to the much higher patient numbers). The bleeding rates were generally lower on 
prasugrel compared with ticagrelor and clopidogrel, which is likely due to the considerably 
higher age in the latter groups. In the PLATO trial, bleeding had occurred with similar 
frequency in the ticagrelor and clopidogrel groups independently of DM status.31, 32 In TRITON-
TIMI 38, although TIMI major haemorrhage was increased among subjects without DM on 
prasugrel (1.6% vs. 2.4%; HR: 1.43; P=0.02), the rates were similar among subjects with DM for 
clopidogrel and prasugrel (2.6% vs. 2.5%; HR: 1.06; P=0.81, P for interaction =0.29).30 
 
Further methodological considerations 
Between registries, substantial differences were found in terms of study setting, eligibility of 
patients, site selection, and definition of endpoints, including bleeding events, which limits the 
comparability of results across the studies. As in the previous analyses, we did not formally 
assess nor adjust or weigh the risk of bias in the various observational studies (transfer of raw 
data was not possible due to data protection). Not all of the previously identified as suitable 
registries8 provided data in the agreed structured format, and therefore such data could not be 
analysed for the purpose of this paper. Data were not differentiated between the various ACS 
types (STEMI, NSTE-ACS, and UA) as not all registries contained data on all groups, and 
resulting group sizes would have been too small for meaningful analyses. After 30 days follow-
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up, rates of missing outcome values (not scheduled or not collected) were high. The statistical 
handling of such data sets is difficult, as a conservative approach (all lost-to-follow-up cases 
counted as affected by an event) will dramatically overestimate the incidence of rare events 
(such as fatal bleeding or death), while another approach that restricts the analysis to those 
patients who can be followed (alive and able to report events reliably) will underestimate the 
true event rates. Lastly, due to limitations in sample size and the limited time span covered in 
our registries we did not assess temporal changes of outcomes. Recently, Bauters et al. 
showed in a metaanalysis of 139 studies/cohorts that the improvements in management of MI 
patients during the last decades have not been associated with a reduction of the gap between 
DM and non-DM patients.33 
 
Conclusions 
PIRAEUS provides a comprehensive picture of the actual outcomes of diabetic patients with 
ACS under clinical practice conditions in multiple countries throughout Europe, and thus 
complements the data from phase III RCTs of the various P2Y12 receptor inhibitors. As 
expected, overall death rates and various other ischaemic outcomes as well as bleeding events 
documented in the registries were higher than in the RCTs. This may reflect the fact that 
consecutive and more-ill patients were included in the registries. As expected, patients with 
DM, compared with those without DM, generally had a higher rate of all-cause death, non-
fatal cardiovascular events (with the exception of recurrent MI), and bleeding events. 
Interpretation of bleeding rates is difficult given the differences between registries (in terms of 
definitions, coronary artery bypass graft (CABG)-related interventions, and different 
femoral/radial access rates).   
Notably, the registries showed considerable differences in setting as well as patient and 
treatment selection. The ischaemic outcomes for the three P2Y12 inhibitors differed 
enormously between registries, most likely driven by the differences in patients’ baseline 
characteristics, in particular, patient age.  
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Figure legends 
 
Figure 1. The column on the left displays the endpoints and the registries with available data in 
the group of patients with (top figure) and without (bottom figure) DM for the respective 
endpoint at the end of the hospitalisation period. The column “Events/N” shows the number 
of events per the number of patients (N) in the respective group. The column “Event rate (95% 
confidence interval)” provides the underlying data for the graph. Squares in the graph 
represent the event rate; the horizontal lines extending from the squares, the 95% confidence 
intervals.  
 
Figure 2. The column on the left displays death and other efficacy endpoints and the registries 
with available data at the end of the hospitalisation period. Further, risk ratios (RR) with 95% 
upper and lower confidence intervals (CI) are given, for patients with and without DM. Squares 
in the graph represent the risk ratio; the horizontal lines extending from the squares, the 95% 
confidence intervals. Diamonds represent the pooled RR (random effects model) of the 
respective endpoints.  The event rates in the CZECH-2 registry for stroke and repeat PCI were 
not calculated as there were no such events in patients without DM. In this registry in patients 
with DM, there were no stroke cases, and one repeat PCI case reported.  
* Not included in pooled estimate due to no event in either DM or no DM group. 
 
 
Figure 3. The graphs show the unadjusted event rate (%) on the y-axis and the mean patient 
age on the x-axis. Each bubble represents a P2Y12 group (green = prasugrel, blue = clopidogrel, 
pink= ticagrelor) within the named registry, and the sizes of the bubbles visualise the number 
of patients in that P2Y12 group.  
Note that in the picture 3b for AMIS-Plus the mortality of patients after discharge is shown.   
 
Figure 4. The column on the left displays the safety/bleeding endpoints and the registries with 
available data for patients with (top figure) and without (bottom figure) DM for the respective 
endpoint at the end of the hospitalisation period. The column “Events/N” shows the number 
of events per the number of patients (N) in the NSTE-ACS cohort. The column “Event rate (95% 
confidence interval)” provides the underlying data for the graph. Squares in the graph 
represent the event rate; the horizontal lines extending from the squares, the 95% confidence 
intervals. 
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Figure 5.  The column on the left displays the death and other efficacy endpoints and the 
registries with available data at the end of the hospitalisation period. Further, risk ratios with 
95% upper and lower confidence intervals are given, for patients with and without DM. 
Squares in the graph represent the risk ratio; the horizontal lines extending from the squares, 
the 95% confidence intervals. Diamonds represent the pooled RR (random effects model) of 
the respective endpoints. 
 
Figure 6. The column on the left displays the risk of in-hospital bleeding events and the 
registries with available data at the end of the hospitalisation period. Further, the risk ratio 
with 95% upper and lower confidence intervals is given. Squares in the graph represent the risk 
ratio; the horizontal lines extending from the squares, the 95% confidence intervals. 
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Table 1. Characteristics and treatment modalities of patients with diabetes mellitus versus those without diabetes mellitus  
Parameter/Characteristic AAPCI/ADAPT AMIS Plus ATACS 
 
Patients with DM  Patients without DM Patients with DM Patients without DM Patients with DM Patients without DM 
Patient number of patients  n = 1218 n = 5152 n = 2350 n = 9510 n = 3020 n = 7076 
              
Methodology             
Definition of (major) bleeding TIMI TIMI .   
Severe / moderate bleeding 
according to GUSTO-criteria 
  
              
Characteristics of patients              
Age, mean ±  SD 66.6 (12.3) 61.7 (13.7) 68.8 (11.7) 64.5 (12.8) 70.4  ± 10.6 65.4  ± 13.2 
        , elderly > 75 years, % 26.8 18.4 826 (35.1) 2249 (23.6) 37.4 27.3 
Gender, males: females, % 66.3: 33.7 69.9: 30.1 72.4: 27.6 76.2: 23.8 67: 33 73.1: 26.9 
ACS type             
        STEMI, % 64.6 70.7 49 57.6 25.7 37.6 
        NSTE-ACS, %  35.4 29.3 51 42.4 74.3 62.4 
Diabetes mellitus, any (type 1 
or 2), % 
100       100   
     Diabetes mellitus, type 1, %             
     Diabetes mellitus, type 2 , %             
HbA1c, mean, %              
insulin-treated, % 29.1    28.4        
Chronic (congestive) heart 
failure, %   
     4.1  1.4     
Atrial fibrillation, %    9 7.9  6.0  3.5 20.3 12.3 
Macrovascular complications 
before the index ACS event 
(CHD, cerebrovascular, 
PAOD), any, % 
        100 100 
    Coronary artery disease 
(CAD, CHD), % 
     41.2  26.2 100 100 
    Previous stroke, % 7 4.4     9.5 5.4 
    Previous myocardial 
infarction (STEMI/NSTEMI), % 
18.2 10.2  23.9  14.5 31.5 23.5 
    Previous PCI, % 23.4 12.4  26.3  15.6 38.3 25 
    Previous CABG, %     10.5  4.2 15.2 8.7 
    Peripheral arterial occlusive 
disease (PAOD), % 
     9.1  3.6 15.3 6.9 
Left ventricular hypertrophy, %               
Arterial hypertension, %      81.8  56 93 75.8 
Current smoking, % 33.1 44.4   34.1  42.6 24.9 39.1 
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Microvascular complications, 
any, %  
            
     Diabetic nephropathy, %             
     Diabetic retinopathy, %             
     Diabetic neuropathy, %             
              
Antithrombotic pretreatment 
before the index ACS event  
            
Patients on chronic aspirin 
(ASA), % 
     56.8  36.5 49 36.4 
Patients on chronic clopidogrel 
/ prasugrel / ticagrelor, % 
C P T C P T C P T C P T C P T  C P T 
 
  
  
  
   
  
  
  14.7  1.2 2.2  7  1.1  0.9 21.7 3.6  15.7 3.8   
Patients on oral anticoagulation 
(VKA or NOAC), % 
     6.6  4.2     
              
ACS characteristics              
Killip class: I / II / III / IV I II III IV I  II III IV I II III IV I  II III IV I II III IV I  II III IV 
  60.0 22.2 5.9 11.9 67.5 21.2 3.9 7.5 79.9 11.2 4.4 4.6 89.1 6.3 1.7 3 86.1 11.4 2.5 91.9 6.3 1.8 
Timings, minutes mean (IQR 
or Standard deviation) 
            
Time from first medical contact 
to PCI,  
223 (298) 199 (279) 167 min (IQR 85, 668 min) 133 min (IQR 75, 370 min)     
              
Intervention during initial 
hospitalisation 
            
Coronary angiography, % 100 100 85.5 89.8 100 100 
PCI, % 84.1 86.3 83.5 88.5 84 85.6 
CABG, % 4.6 2.7  2.8; planned 5.1  1.6; planned 2.6 2.7 2.6 
PCI access radial, (%   28.2  29.8   29.9   33.2  24.8 23.8 
Repeat revascularisation during  
same hospital stay,  % 
12.9 11.4 
  
5.4 5.4 
       
TREATMENT       
I) Treatment for ACS index 
event before hospital (pre-
hospital) 
      
Patients with available data at 
this time point, n 
n=1212 n=5133     
Clopidogrel, % overall 
29.4 32     
   , loading dose …. % 
100 100     
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Prasugrel, % overall 
12.1 14.4     
  , loading dose ….. % 
100 100     
Ticagrelor, % overall 
12 14.5     
     , loading dose …. % 
100 100     
Aspirin (ASA), % 
95.8 97     
GPIIb/IIIa inhibitors, % 
0.6 0.2     
Unfractionated heparin (UFH), 
% 
59.2 67.4     
Low molecular weight heparin 
(LMWH), % 
24 21.3     
Fondaparinux, % 
1.3 1     
 
      
II) Treatment in hospital 
      
Patients with available data at 
this  time point, n 
n=1212 n=5133 n=2350 n=9510 n=3020 n=7076 
Clopidogrel , % overall 
18.4 14.3 46.3 38.1 79.3 71.7 
       , loading dose was given in 
…. % 
100 100   63.6 61 
Prasugrel, % overall 
9.7 9.9 19.3 25.6 23.9 32.6 
    ,  loading dose was given in 
…. % 
100 100   19 27.1 
Ticagrelor, % overall 
5.3 6 34.4 36.3   
     , loading dose was given  
…. % 
100 100     
Switching from clopidogrel to 
prasugrel,  % 
0.9 2.3 79/1022 (7.7) 499/3568 (14) 1.8 2.5 
Switching from clopidogrel to 
ticagrelor,  % 
0.7 0.6 30/732 (4.1) 132/2461 (5.4)   
Switching from 
ticagrelor/prasugrel to 
clopidogrel, % 
0 0 117/1261 (9.3) 433/6046 (7.2) 0.8 0.7 
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Aspirin (ASA), % 
  100 100 100 100 
GPIIb/IIIa inhibitors, % 
25.6 28.8 280/2295 (12.2) 1457/9346 (15.6) 13.7 19.7 
Unfractionated heparin, % 
  1646/2324 (70.8) 7056/9432 (74.8) 93.6 93.4 
Low molecular weight heparin, 
% 
  541/2304 (23.5) 2329/9360 (24.9) 5.6 4.2 
Fondaparinux, % 
  118/2297 (5.1) 434/9330 (4.7) 6 4.4 
 
      
III) Information on treatment 
at hospital discharge/ after 
hospital discharge?   
D After D After D After D After D After D After 
Patients with available data at 
these 2 time points, n /n 
    n=2071  n=8810  n=3020  n=7076  
Clopidogrel treatment at 
discharge/after discharge,   % / 
% 
    45.9  35.1  72.1  63.1  
Prasugrel treatment at 
discharge / after discharge,     
% / % 
    25.4  34.1  21.3  30.1  
Ticagrelor treatment at 
discharge / after discharge,     
% / % 
    28.6  30.8      
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Table 1 continued 
Parameter/Characteristic Belgian STEMI CZECH2 DIOCLES 
 
Patients with DM Patients without DM Patients with DM Patients without DM Patients with DM Patients without DM 
Patient number of patients n = 365 n = 1914 n = 302 n = 545 n = 786 n = 1755 
       
Methodology 
      
Definition of (major) bleeding 
  
TIMI major 
   
       
Characteristics of patients 
      
Age, mean ± SD 65.6 ± 11 62.3 ± 13 71 ± 10 67 ± 13 71 ± 11 66 ± 13 
, elderly > 75 years, % 86 (23) 356 (19) 
  
37 28.1 
Gender, males: females, % 69: 31 77:23 61:39 70:30 71.0:29.0 75.9:24.1 
ACS type 
      
STEMI, % 100 100 29 41 22.1 34.6 
NSTE-ACS, % 
  
71 59 77.9 65.4 
Diabetes mellitus, any (type 1 
or 2), % 
100 
   
100 
 
Diabetes mellitus, type 1, % 
  
3.7 
   
Diabetes mellitus type 2 , % 
  
96.3 
   
HbA1c, mean, % 
      
insulin-treated, % 
  
35.8 
 
37.2 
 
Chronic (congestive) heart 
failure, %     
12.4 3.2 
Atrial fibrillation, % 
  
14.6 11 8.8 AF/flutter 6.6 AF/flutter 
Macrovascular complications 
before the index ACS event 
(CHD, cerebrovascular, 
PAOD), any, % 
    
50.9 29.6 
Coronary artery disease (CAD, 
CHD), % 
24 15 
  
39.2 22.7 
Previous stroke, % 
  
11 6 10.1 5.5 
Previous myocardial infarction 
(STEMI/NSTEMI), %   
31 21 31.6 17.3 
Previous PCI, % 
  
24.8 17.2 25.5 14.5 
Previous CABG, % 
  
12.9 8.6 6.7 3.6 
Peripheral arterial occlusive 
disease (PAOD), % 
11 6 
  
14.6 6.4 
Left ventricular hypertrophy, % 
      
Arterial hypertension, % 70 44 87.1 60.7 80.3 59.3 
Current smoking, % 32 43 22 35 18.4 32.9 
Microvascular complications, 
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any, % 
Diabetic nephropathy, % 
    
Severe CKD 
(creat>=2/dialysis/transplant)=9.2  
Diabetic retinopathy, % 
      
Diabetic neuropathy, % 
      
       
Antithrombotic pretreatment 
before the index ACS event       
Patients on chronic aspirin 
(ASA), %   
53 32 56.4 33.4 
Patients on chronic clopidogrel 
/ prasugrel / ticagrelor, % 
C P T C P T C P T C P T C P T C P T 
       
10 0 0 5.6 0.2 0 20.4 0.8 0 12.6 1.4 0 
Patients on oral anticoagulation 
(VKA or NOAC), %   
8.3 6.6 11 10.9 
       
ACS characteristics 
      
Killip class: I / II / III / IV I II III IV I II III IV I II III IV I II III IV I II III IV I II III IV 
 
81 8 4 7 83 8 2 7 70 17 10 3 72 17 7 4 76.7 13.3 7.4 2.6 89.3 6.1 2.9 1.7 
Timings, minutes mean (IQR 
or Standard deviation) 
n=285 n=1530 
    
Time from first medical contact 
to PCI 
123 (IQR 60-132) 114 (IQR 50-112) ND 
 
Median (P25-P75) = 125 (90-168) 124 (88-200) 
       
Intervention during initial 
hospitalisation       
Coronary angiography, % 
  
70.4 76 81.3 85.2 
PCI, % 91 94 63.9 50.3 55.5 63.5 
CABG, % 2 1 
  
3.2 (in additional 3.3 scheduled after 
discharge) 
2.5 (in additional 1.6 scheduled 
after discharge) 
PCI access radial % 
  
ND 
 
71  77.4  
Repeat revascularization during  
same hospital stay,  %   
0 0.3 
  
       
TREATMENT       
I) Treatment for ACS index 
event before hospital (pre-
hospital) 
      
Patients with available data at 
this time point, n 
      
Clopidogrel, % overall 
      
, loading dose % 
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Prasugrel, % overall 
      
, loading dose  % 
      
Ticagrelor, % overall 
      
, loading dose % 
      
Aspirin (ASA), % 
      
GPIIb/IIIa inhibitors, % 
      
Unfractionated heparin (UFH), 
% 
      
Low molecular weight heparin 
(LMWH), % 
      
Fondaparinux, % 
      
 
      
II) Treatment in hospital 
    
Includes pre-hospital (only overall 
data recorded) 
Includes pre-hospital (only overall 
data recorded) 
Patients with available data at 
this  time point, n 
    n =784 n=1752 
Clopidogrel , % overall 
    90.2 90 
, loading dose was given in …. 
% 
    61.4 67.8 
Prasugrel, % overall 
    5 5.8 
,  loading dose was given in …. 
% 
    1.5 2.9 
Ticagrelor, % overall 
    0 0 
, loading dose was given  …. % 
    0 0 
Switching from clopidogrel to 
prasugrel,  % 
      
Switching from clopidogrel to 
ticagrelor,  % 
      
Switching from 
ticagrelor/prasugrel to 
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clopidogrel, % 
Aspirin (ASA), % 
    97.3 97.7 
GPIIb/IIIa inhibitors, % 
    7.3 11.2 
Unfractionated heparin, % 
    11.2 16.8 
Low molecular weight heparin, 
% 
    80.2 73.4 
Fondaparinux, % 
    6.7 7.6 
 
      
III) Information on treatment 
at hospital discharge/ after 
hospital discharge? 
D After D After D After D After D After D After 
Patients with available data at 
these 2 time points, n /n 
n=304  n=1645  n=287  n=501  n=740  n=1708  
Clopidogrel treatment at 
discharge/after discharge,   % / 
% 
15  11  72  79  71.2  70.8  
Prasugrel treatment at 
discharge / after discharge,     
% / % 
28  28  0.3  1.2  7.4  6.4  
Ticagrelor treatment at 
discharge / after discharge,     
% / % 
57  61  1  1.2  0  0  
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Table 1 continued 
Parameter/Characteristic MULTIPRAC Newcastle 2015 SCAAR 
 
Patients with DM Patients without DM Patients with DM Patients without DM Patients with DM Patients without DM 
Patient number of patients  n = 279 n = 1756 n = 392 n = 1487 n = 19794 n = 66595 
              
Methodology             
Definition of (major) bleeding 
major bleedings = requiring 
transfusions 
    
Fatal, cerebral, requiring 
surgery/transfusion 
Fatal, cerebral, requiring 
surgery/transfusion 
              
Characteristics of patients              
Age, mean ± SD 64.0 ± 11.51 60.3 ± 12.10 66.66 ± 12.18 65.47 ± 12.91 69.1 ± 10.6 67.6 ± 11.6 
        , elderly > 75 years, % >= 75years: 18.6 >= 75years: 13.3 28.57 25.69 30.2 27.8 
Gender, males: females, % 71.0:29.0 79.3:20.7 69:31 73:27 67.3:32.7 69.3:30.7 
ACS type           
        STEMI, % 100 100 30.1 43.71 32.9 41 
        NSTE-ACS, %  0 0 69.9 56.29 67.1 59 
Diabetes mellitus, any (type 1 or 
2), % 
    
20.86  
100   
     Diabetes mellitus, type 1, %     30.61      
     Diabetes mellitus type 2 , %     69.39      
HbA1c, mean, %        
 
  
insulin-treated, % 27.6     48.8   
Chronic (congestive) heart 
failure, %   
6.8 1.7 
4.59 2.42 
16.2 6.7 
Atrial fibrillation, %          9.6 6.7 
Macrovascular complications 
before the index ACS event 
(CHD, cerebrovascular, PAOD), 
any, % 
    
60.46 40.01 
45.9 25.7 
    Coronary artery disease (CAD, 
CHD), % 
    
55.36 35.84 
37 19.6 
    Previous stroke, % 7.9 3.5 12.25 5.85 13.3 7.3 
    Previous myocardial infarction 
(STEMI/NSTEMI), % 
17.2 10.5 
39.03 24.01 
32.1 16.6 
    Previous PCI, % 13.6 8.5 32.14 18.7 20.1 10.7 
    Previous CABG, % 3.9   10.2 3.43 12.8 5.5 
    Peripheral arterial occlusive 
disease (PAOD), % 
    
13.27 5.65 
7.6 3.4 
Left ventricular hypertrophy, %               
Arterial hypertension, %     
 
 74.5 46.5 
Current smoking, %     21.94 31.94 19.9 25 
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Microvascular complications, 
any, %  
            
     Diabetic nephropathy, %     
  
27.2 18.3 
     Diabetic retinopathy, %             
     Diabetic neuropathy, %             
              
Antithrombotic pretreatment 
before the index ACS event  
            
Patients on chronic aspirin 
(ASA), % 
29.4 13.7 50 32.01 48.9 26.8 
Patients on chronic clopidogrel / 
prasugrel / ticagrelor, % 
C P T C p T C P T C P T C P T C P T 
  3.9 0.4 0 2.5 0.1 0 14.8 1.53 2.81 8.07 1 2 7.3 0.1 0.5 3.5 0.0 0.2 
Patients on oral anticoagulation 
(VKA or NOAC), % 
    
  
6.3 3.8 
              
ACS characteristics      
 
  
 
  
Killip class: I / II / III / IV I II III IV I II I II I II I II I  II III IV I II III IV I  II III IV 
  84.4 8 3.3 4.2 93.9 3.8 1.1 1.1         59.1 3.6 1.1 1.5 62.6 2.4 0.6 1.2 
Timings, minutes mean (IQR or 
Standard deviation) 
            
Time from first medical contact to 
PCI 
STEMI diagnosis to PCI: Median 91 
(IQR 69-127) 
STEMI diagnosis to PCI: Median 
83 (IQR 64-116) 
  5h53min ± 7h09m 5h0m ± 6h44m 
            
Intervention during initial 
hospitalisation 
          
Coronary angiography, % 100 100   100 100 
PCI, % Revascularization: 97.5% Revascularization: 96.4%   73.3 78.6 
CABG, % see PCI% see PCI%   6.7 4.7 
PCI access radial %   49.5  46.8    59.5  62.5  
Repeat revascularisation during  
same hospital stay,  % 
1.1 urgent repeat PCI, 0 urgent 
CABG 
0.8 urgent repeat PCI, 0.1 urgent 
CABG 
  0.9 0.8 
       
TREATMENT       
I) Treatment for ACS index 
event before hospital (pre-
hospital) 
           
Patients with available data at 
this time point, n 
n = 279 n = 1756   n=19794 n=66595 
Clopidogrel, % overall 
60.9% 53.3%   48.8 50.2 
   , loading dose was given in 
…. % 
300mg: 19.4%; 600mg: 80.6%  
300mg: 14.9%; >300 to ≤ 600mg: 
85.1%  
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Prasugrel, % overall 
39.1% 46.7%   1.8 2.1 
  , loading dose was given in 
….. % 
60 mg: 100 % 
60 mg: 99.4 %; 40 mg 0.2%, 50mg 
0.2%, 80mg 0.1% 
      
Ticagrelor, % overall 
0 0   16.5 18 
     , loading dose was given  
…. % 
0 0       
Aspirin (ASA), % 
96.4 96.2   69.7 72.8 
GPIIb/IIIa inhibitors, % 
6.1 5.1   1 1.3 
Unfractionated heparin (UFH), 
% 
63.1 69.2   11.4 14.2 
Low molecular weight heparin 
(LMWH), % 
22.9 19.4   4.7 4.7 
Fondaparinux, % 
0.7 0.9   24.5 24.2 
 
           
II) Treatment in hospital 
           
Patients with available data at 
this  time point, n 
      n = 19794 n=66595 
Clopidogrel , % overall 
    4.4 5.2 
       , loading dose was given in 
…. % 
           
Prasugrel, % overall 
      1.7 2.1 
    ,  loading dose was given in 
…. % 
          
Ticagrelor, % overall 
      3.3 3.7 
     , loading dose was given  
…. % 
          
Switching from clopidogrel to 
prasugrel,  % 
45.3 49.3   2.9 3.2 
Switching from clopidogrel to 
ticagrelor,  % 
11.2 11.6   20 22.6 
Switching from 
ticagrelor/prasugrel to 
Prasu to clopi: 8.3 Prasu to clopi: 8.3   4.4 4.7 
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clopidogrel, % 
Aspirin (ASA), % 
16.9 13.8   3.9 5 
GPIIb/IIIa inhibitors, % 
27.7 32.1   11.2 13.6 
Unfractionated heparin, % 
50.7 45.8   55.8 56.8 
Low molecular weight heparin, 
% 
0.7 1.7   2.5 2.5 
Fondaparinux, % 
2.5 2.6   0.3 0.4 
 
      
III) Information on treatment 
at hospital discharge/ after 
hospital discharge?   
D After D After D After D After D After D After 
Patients with available data at 
these 2 time points, n /n 
            n=19794   n=66595   
Clopidogrel treatment at 
discharge/after discharge,   % / 
% 
27.6   23.7         61.3   62.7   
Prasugrel treatment at 
discharge / after discharge,     
% / % 
61.6   66.7         2.2   2.1   
Ticagrelor treatment at 
discharge / after discharge,     
% / % 
7.5   7.6         19.7   22.2   
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Table 1 continued 
Parameter/Characteristic SPUM-ACS 
 
Patients with DM Patients without DM 
Patient number of patients  n = 399 n = 1769 
      
Methodology     
Definition of (major) bleeding     
      
Characteristics of patients      
Age, mean ± SD 66.5 ± 12 63.1 ± 12 
        , elderly > 75 years, % 30.1 19.4 
Gender, males: females, % 80:20 78.3:21.7 
ACS type     
        STEMI, % 42.1 55.1 
        NSTE-ACS, %  51.1 41.1 
Diabetes mellitus, any (type 1 or 
2), % 
    
     Diabetes mellitus, type 1, %     
     Diabetes mellitus type 2 , %     
HbA1c, mean, %   7.6 (n=181)   
insulin-treated, % 28.6   
Chronic (congestive) heart 
failure, %   
2.8 1.2 
Atrial fibrillation, %        
Macrovascular complications 
before the index ACS event 
(CHD, cerebrovascular, PAOD), 
any, % 
    
    Coronary artery disease (CAD, 
CHD), % 
    
    Previous stroke, % 4.3 1.8 
    Previous myocardial infarction 
(STEMI/NSTEMI), % 
23.6 13.1 
    Previous PCI, % 25.8 15.7 
    Previous CABG, % 10.3 4.6 
    Peripheral arterial occlusive 
disease (PAOD), % 
10.5 4.6 
Left ventricular hypertrophy, %       
Arterial hypertension, % 78.2 54 
Current smoking, % 30.1 41.9 
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Microvascular complications, 
any, %  
    
     Diabetic nephropathy, %     
     Diabetic retinopathy, %     
     Diabetic neuropathy, %     
      
Antithrombotic pretreatment 
before the index ACS event  
    
Patients on chronic aspirin 
(ASA), % 
54.6 27.7 
Patients on chronic clopidogrel / 
prasugrel / ticagrelor, % 
C P T C P T 
  14.8 3.2 0.8 7.2 0.5 0.1 
Patients on oral anticoagulation 
(VKA or NOAC), % 
4.8 3.3 
      
ACS characteristics  n=397 n=1754 
Killip class: I / II / III / IV I II III IV I  II III IV 
  83.7 9.5 3 3.3 87.6 8.4 1.5 2.5 
Timings, minutes mean (IQR or 
Standard deviation) 
    
Time from first medical contact to 
PCI 
211 ± 296 min 176 ± 254 min 
      
Intervention during initial 
hospitalisation 
    
Coronary angiography, % 100 100 
PCI, % 94.7 96.6 
CABG, % 5.3 3.4 
PCI access radial versus 
femoral, %   
    
Repeat revascularisation during  
same hospital stay,  % 
0 0 
   
TREATMENT   
I) Treatment for ACS index 
event before hospital (pre-
hospital) 
    
Patients with available data at 
this time point, n 
n=399 n=1754 
Clopidogrel, % overall 
14.8 7.2 
   , loading dose was given in …. 
% 
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Prasugrel, % overall 
3.2 0.5 
  , loading dose was given in ….. 
% 
    
Ticagrelor, % overall 
0.8 0.1 
     , loading dose was given  …. 
% 
    
Aspirin (ASA), % 
54.6 27.7 
GPIIb/IIIa inhibitors, % 
    
Unfractionated heparin (UFH), % 
    
Low molecular weight heparin 
(LMWH), % 
    
Fondaparinux, % 
    
 
    
II) Treatment in hospital 
    
Patients with available data at 
this  time point, n 
n = 399 n= 1768 
Clopidogrel , % overall 
68.9 74.5 
       , loading dose was given in 
…. % 
75.2 71.5 
Prasugrel, % overall 
23.1 32.2 
    ,  loading dose was given in 
…. % 
18.5 28.1 
Ticagrelor, % overall 
6.3 5 
     , loading dose was given  …. 
% 
5.8 4.8 
Switching from clopidogrel to 
prasugrel,  % 
2.3 0.3 
Switching from clopidogrel to 
ticagrelor,  % 
0 1.5 
Switching from 
ticagrelor/prasugrel to 
clopidogrel, % 
0.3 0 
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Aspirin (ASA), % 
72.4 86.1 
GPIIb/IIIa inhibitors, % 
22.1 28.1 
Unfractionated heparin, % 
94.2 95.9 
Low molecular weight heparin, % 
4.3 5.6 
Fondaparinux, % 
4.3 3.8 
 
  
III) Information on treatment at 
hospital discharge/ after 
hospital discharge?   
D After D After 
Patients with available data at 
these 2 time points, n /n 
n=389 n=382/352 n=1746 n=1711/1638 
Clopidogrel treatment at 
discharge/after discharge,   % / 
% 
51.2 51.0/43.8 46.6 47.4/39.2 
Prasugrel treatment at discharge 
/ after discharge,     % / % 
32.9 32.7/31 41.5 39.9/34.1 
Ticagrelor treatment at discharge 
/ after discharge,     % / % 
5.1 5/4.5 5.7 4.8/4.5 
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Table 2. Endpoints in patients with and without DM 
  AAPCI/ADAPT AMIS-Plus ATACS Belgian STEMI CZECH-2 DIOCLES MULTIPRAC Newcastle 2015 SCAAR SPUM-ACS 
  DM  No DM DM No DM DM No DM DM No DM DM No DM DM No DM DM No DM DM No DM DM No DM DM No DM 
All-cause death 
 
         
in hospital 6.40 3.30 4.98 2.57 2.78 1.77 9.42 6.63 3.65 6.13 5.85 2.62 1.43 0.34 2.30 1.89 3.73 2.42 2.51 1.24 
30 days 
        
7.93 8.64 7.45 3.17 
  
3.32 3.10 4.94 3.08 2.76 1.93 
180 days  
          
10.72 5.69 
  
5.11 5.63 8.00 4.65 
  
1 year  
  
6.93 3.23 
        
3.27 2.29 7.48 8.17 10.45 5.91 7.12 3.89 
CV death  
              
  
    
in hospital 
  
2.98 1.29 
        
1.43 0.28   
  
2.26 1.19 
30 days 
              
  
  
2.51 1.76 
180 days  
              
  
    
1 year  
            
1.82 0.97   
  
5.60 3.03 
CV events 
              
  
    
in hospital 0.90 1.09 
          
2.51 1,42   
  
4.51 2.77 
30 days 
              
  
  
6.53 4.31 
180 days  
              
  
    
1 year  
              
  
  
17.05 9.66 
Stroke  
              
  
    
in hospital 0.49 0.49 0.94 0.54 0.43 0.18 
  
0 0 0.76 1.20 0 0.23   
  
1.00 0.34 
30 days 
        
0.34 0 
    
  0.44 0.44 1.76 0.40 
180 days  
          
1.31 1.58 
  
  1.67 1.23 
  
1 year  
  
0.76 0.37 
          
  2.66 1.78 3.56 0.86 
Recurrent MI  
              
  
    
in hospital 0.41 0.62 0.98 0.58 0.13 0.34 
  
0.33 0.56 1.78 3.48 0 0.23   
  
1.00 0.96 
30 days 
        
1.38 1.18 
    
  7.94 7.19 1.51 1.36 
180 days  
          
3.01 4.57 
  
  13.45 10.08 
  
1 year  
  
5.33 3.28 
          
  16.32 11.51 5.34 2.92 
Repeat PCI  
              
  
    
in hospital 12.89 11.39 
  
5.36 5.38 
  
0.33 0 
  
1.08 0.80   
  
1.25 0.79 
30 days 
        
1.03 0.20 
    
  
  
2.01 1.70 
180 days  
              
  
    
1 year  
              
  
  
7.89 5.77 
Fatal/life-
threating 
bleeding 
              
  
    
in hospital 
  
0.04 0.08 
      
0.25 0.06 
  
  0.02 0.04 1.75 0.90 
30 days 
              
  
  
1.76 1.13 
180 days  
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1 year  
              
  
  
1.78 1.94 
Major bleeding  
              
  
    
in hospital 1.40 1.20 0.98 0.82 1.29 0.99 
  
0.66 0.93 3.82 2.68 2.15 0.46   1.42 1.04 1.25 1.07 
30 days 
        
1.03 1.38 
    
  
  
1.26 1.30 
180 days  
              
  
    
1 year  
              
  
  
2.04 2.06 
Minor bleeding  
              
  
    
in hospital 
  
1.62 1.56 
        
2.87 5.87   
  
2.01 2.32 
30 days 
              
  
  
2.01 2.61 
180 days  
              
  
    
1 year                                    4.33 4.35 
 
Numbers show the incidence rates of various effectiveness and safety (bleeding) outcomes at various time points, in the total ACS populations (STEMI and NSTE-ACS combined) in each study 
(across treatments).  
Empty fields show that the respective parameter has not been collected at this time point in a given registry.  
No summary statistics across all studies were generated.  
Empty cells denote that data were not collected or not provided for this review. 
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Table 3. Endpoints in patients with and without DM, by P2Y12 receptor inhibitor DAPT  
 
  AAPCI/ADAPT AMIS-Plus ATACS DIOCLES 
 
DM No DM Diabetes No DM Diabetes No DM Diabetes No DM 
  P T C P T C P T C P T C P T C P T C P T C P T C 
All-cause death 
                        
in hospital 2.64 5.24 6.51 1.28 2.08 3.48 3.75 3.58 6.53 1.97 1.71 3.78 1.43 
 
3.00 1.19 
 
1.97  
 
5.10 0.98 
 
2.55 
30 days 
                  
 
 
6.75 
  
3.23 
180 days  
                  
 
 
10.04 
  
5.45 
1 year  
      
1.23 6.62 9.26 1.53 2.33 4.65 
      
 
     
CV death  
                  
 
     
in hospital 
      
1.99 2.35 3.86 0.90 0.78 2.04 
      
 
     
30 days 
                  
 
     
180 days  
                  
 
     
1 year  
                  
 
     
CV events 
                  
 
     
in hospital 1.13 0 1.23 0.88 0.85 1.17 
            
 
     
30 days 
                  
 
     
180 days  
                  
 
     
1 year  
                  
 
     
Stroke  
                  
 
     
in hospital 0.75 0 0.53 0.16 0.47 0.52 0.22 0.74 1.38 0.16 0.52 0.80 0.32 
 
0.47 0.05 
 
0.24  
 
0.73 0.98 
 
1.11 
30 days 
                  
 
     
180 days  
                  
 
 
1.20 
  
1.48 
1 year  
      
0 0 1.58 0.22 0.17 0.59 
      
 
     
Recurrent MI  
                  
 
     
in hospital 0.38 0 0.70 0.72 0.38 0.65 1.32 0.74 1.01 0.57 0.41 0.75 0.16 
 
0.09 0.30 
 
0.35  
 
1.90 7.84 
 
3.33 
30 days 
                  
 
     
180 days  
                  
 
 
3.15 
  
4.44 
1 year  
      
2.60 4.00 7.29 4.04 1.75 3.90 
      
 
     
Repeat PCI  
                  
 
     
in hospital 13.58 15.24 12.85 13.99 10.01 11.18 
      
6.36 
 
4.89 5.73 
 
5.18  
     
30 days 
                  
 
     
180 days  
                  
 
     
1 year  
                  
 
     
Fatal/life-threating 
bleeding                   
 
     
in hospital 
      
0 0 0.09 0.08 0.12 0.06 
      
 
 
0.29 0 
 
0.07 
30 days 
                  
 
     
180 days  
                        
1 year  
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Major bleeding  
                        
in hospital 0.38 1.90 1.06 0.64 1.04 0.78 0.44 0.87 1.29 0.82 0.93 0.72 0.95 
 
1.41 0.89 
 
1.06 
  
3.79 0.98 
 
2.94 
30 days 
                        
180 days  
                        
1 year  
                        
Minor bleeding  
                        
in hospital 
      
1.55 2.97 0.64 1.36 2.43 0.86 
            
30 days 
                        
180 days  
                        
1 year                                                  
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Table 3 continued 
 
  MULTIPRAC Newcastle 2015 SCAAR SPUM-ACS 
 
DM No DM DM No DM DM No DM DM No DM 
  P T C P T C P T C P T C P T C P T C P T C P T C 
All-cause death 
      
 
            
in hospital 1.03 
 
1.43 0.41 
 
0.56  0 0  0 0 4.71 3.62 3.53 2.01 2.25 2.17 0  0 0 0 0.12 
30 days 
      
 0 0.46  1.37 0.86 5.44 4.57 4.67 2.62 2.79 2.76 0  1 0.69 0 0.86 
180 days  
      
 0 3.47  3.53 2.23 7.50 7.11 7.30 3.49 3.88 4.24 
 
 
    
1 year  1.06 
 
4.35 1.66 
 
5.07   5.36  6.18 3.45 8.97 8.83 9.64 4.21 4.48 5.54 0.80  7.50 1.54 
 
3.09 
CV death  
      
      
       
 
    
in hospital 1.03 
 
1.43 0.27 
 
0.56       
      
0  0 0 0 0.12 
30 days 
      
      
      
0  0.50 0.68 0 0.61 
180 days  
      
      
       
 
    
1 year  1.06 
 
2.90 0.41 
 
2.54       
      
0.8  5.00 1.54 
 
1.61 
CV events 
      
      
       
 
    
in hospital 3.09 
 
1.43 1,37 
 
2.53       
      
1.56  2.48 1.10 3.00 1.84 
30 days 
      
      
      
3.13  4.98 2.76 4.00 3.44 
180 days  
      
      
       
 
    
1 year  
      
      
      
9.6  18 7.12 
 
9.41 
Stroke  
      
      
       
 
    
in hospital 0 
 
0 0.27 
 
0.56       
      
0  0.99 0 0 0.37 
30 days 
      
      0.75 0.54 0.32 0.41 0.31 0.43 0.78  1.99 0 0 0.49 
180 days  
      
      1.12 1.81 1.52 0.91 0.84 1.15 
 
 
    
1 year  
      
      2.05 2.17 2.48 1.37 1.22 1.63 0.8  4.5 0.56 0 0.87 
Recurrent MI  
      
      
       
 
    
in hospital 0 
 
0 0.14 
 
0.28       
      
1.56  0.5 0.97 2.00 0.98 
30 days 
      
      6.34 7.22 7.27 6.65 7.04 6.81 1.56  1 1.24 3 1.47 
180 days  
      
      9.51 11.73 13.02 8.52 9.33 9.86 
 
 
    
1 year  
      
      12.13 14.17 15.9 9.57 10.5 11.46 4.00  5.5 2.23 
 
3.59 
Repeat PCI  
      
      
       
 
    
in hospital 2.06 
 
0 0.82 
 
1.40       
      
1.56  1.49 0.97 2.00 0.61 
30 days 
      
      
      
2.34  2.49 2.21 3.00 1.35 
180 days  
      
      
       
 
    
1 year  
      
      
      
8.00  9.00 5.59 
 
6.19 
Fatal/life-threating bleeding 
      
      
       
 
    
in hospital 
      
      0 0.03 0.01 0.04 0.04 0.04 0.78  1.98 0.28 0 0.61 
30 days 
      
      
      
0.78  1.99 0.28 0 0.74 
180 days  
      
      
       
 
    
1 year  
      
      
      
0.80  2 1.12 
 
1.49 
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Major bleeding  
      
      
       
 
    
in hospital 0 
 
4.29 0.55 
 
0.56       0.44 1.33 1.52 0.90 0.80 1.06 0  0.99 0.55 0 0.74 
30 days 
      
      
      
0  1.00 0.83 0 0.98 
180 days  
      
      
       
 
    
1 year  
      
      
      
0  1.50 1.54 1.01 1.86 
Minor bleeding  
      
      
       
 
    
in hospital 2,06 
 
2.86 3.71 
 
5.34       
      
0  3.47 2.21 0 2.70 
30 days 
      
      
      
0  3.48 2.35 0 3.19 
180 days  
      
      
       
 
    
1 year                                0  7.00 3.63 3.03 4.95 
 
Numbers show the incidence rates of various effectiveness and safety (bleeding) outcomes at various time points, for prasugrel (P), ticagrelor (T), and clopidogrel (C). Empty fields show that the 
respective parameter has not been collected at this time point. Data from DIOCLES on prasugrel, data from Newcastle 2015 and from SPUM-ACS on ticagrelor were not included in analyses due to 
the small number of patients. 
No summary statistics across all studies were generated.  
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Figure 1. In-hospital event rates in the various registries, (a) in patients with DM and (b) without 
DM  
a. 
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b. 
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Figure 2. Risk (ratio) of in-hospital death and cardiovascular events in the various registries in 
patients with DM compared with patients without DM 
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Figure 3. All-cause death rates (%) at the end of the hospital stay (a) and at 1 year followup (b) in 
patients with DM, by age and P2Y12 inhibitor  
a.  
  
b. 
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Figure 4. In-hospital bleeding rates (%) in the individual registries, for patients with (top) and 
without (bottom) DM  
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Figure 5. Risk (ratio) of in-hospital bleeding events in the various registries for patients with DM vs. 
patients without DM 
 
 
 
  
 49 
 
Figure 6. Major bleeding rates (%) at the end of the hospital stay in patients with diabetes mellitus, 
by age and P2Y12 inhibitor  
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